The influences of transcription factors on distant cells may mediate important malignant signaling pathways that permit disease progression.
Nevertheless, NF-κB known to mediate malignant transformation is constitutively upregulated in this tumor type via multiple mechanisms.
Therefore, we hypothesized that Metnase may mediate the resistance of malignant cells to Topo IIα inhibitors, and chose to test this in breast cancer cells because anthracyclines are among the most important agents in the treatment of this disease [1], [20] [22].
In these cells, IGF-IR activation enhanced cell adhesion and motility, suggesting that IRS-2 may mediate these aspects of the malignant phenotype.
Gruber et al (1999) showed that in hairy cell leukaemia, another type of chronic B-cell leukaemia, the leukemic cells express bFGF, which in turn, may mediate the resistance to chemotherapy and survival of the malignant cells.
So while expression of CCL2, probably in concert with CCL5, might mediate tumor rejection, CCL2 in concert with TGFβ may mediate myeloid-derived suppressor cell and/or inflammatory monocyte promotion of disseminated malignant cell survival.
Considering the mutual relationship between these neoplastic processes, it is conceivable that NDRG1 may mediate a series of programmatic changes, either directly or indirectly, and eventually facilitates progression of the tumor cell to a more malignant phenotype.
Glutamatergic dysfunction may mediate some of these symptoms.
These specific regions may mediate the, specific effects of acupuncture.
Some experts believe that they may mediate the effects of other cannabinoids.
